

Gelid[®]

Sodium alginate 10 gm & Potassium Bicarbonate 2gm/100 ml suspension
Sodium Alginate BP 500 mg & Potassium Bicarbonate BP 100mg
Chewable Tablet

DESCRIPTION

Gelid[®] is a combined preparation of sodium alginate & potassium bicarbonate. This acts as an Anti-regurgitant agent. On ingestion the suspension reacts with gastric acid to rapidly form a raft of alginic acid gel having a near-neutral pH which floats on the stomach contents effectively impeding gastro-oesophageal reflux for up to 4 hours, and protecting the oesophagus from acid, pepsin and bile. In severe cases the raft itself may be refluxed into the oesophagus in preference to the stomach contents and exert a demulcent effect. In addition in vitro evidence has shown that the raft has a secondary action and is able to entrap bile and pepsin within its structure, further protecting the oesophagus from these gastric components.

INDICATIONS

Treatment of symptoms resulting from the reflux of acid, bile and pepsin into the oesophagus such as acid regurgitation, heartburn, indigestion (occurring due to the reflux of stomach contents), for instance, after gastric surgery, as a result of hiatus hernia, during pregnancy, accompanying reflux oesophagitis, including symptoms of laryngopharyngeal reflux such as hoarseness and other voice disorders, sore throats and cough. Can also be used to treat the symptoms of gastro-oesophageal reflux during concomitant treatment with or following withdrawal of acid suppressing therapy.

DOSAGE & ADMINISTRATION

Oral Liquid (Administered after meals and at bedtime):

- Adults and Children > 12 years: Take 10-20 mL.
- Children 6-12 years: Take 5-10 mL.

Chewable Tablet (The tablet must be chewed thoroughly before swallowing):

- Adults and Children > 12 years: 2-4 tablets.

CONTRAINDICATIONS

Hypersensitivity to any of the ingredients, including the esters of hydroxybenzoates (parabens).

SIDE EFFECTS

Very rarely patients may develop allergic manifestations such as urticaria or bronchospasm, anaphylactic or anaphylactoid reactions.

PRECAUTION & WARNING

Each 10 mL dose has a sodium content of 106 mg (4.6 mmol) and a potassium content of 78 mg (2.0 mmol). This should be taken into account when a highly restricted salt diet is recommended, e.g. in some cases of congestive cardiac failure and renal impairment or when taking drugs which can increase plasma potassium levels. Each 10 mL contains 200 mg (2.0 mmol) of calcium carbonate. Care needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi. There is a possibility of reduced efficacy in patients with very low levels of gastric acid. Treatment of children younger than 12 years of age is not generally recommended, except on medical advice. If symptoms do not improve after seven days, the clinical situation should be reviewed.

USE IN PREGNANCY & LACTATION

An open, uncontrolled study on pregnant women did not demonstrate any significant adverse effects of this suspension on the course of pregnancy or on the health of the foetus/new-born child. Based on this and previous experience, this suspension may be used during pregnancy and lactation.

PHARMACEUTICAL PRECAUTION

Keep away from light, store in a cool and dry place. Keep out of reach of children.

PACKAGING

Gelid[®] 2.5 Suspension: Bottle containing 100mL of suspension. Each 100 mL contains sodium alginate 10 gm & potassium bicarbonate 2 gm.

Gelid[®] 2.5 Tablet: Box containing strips of chewable tablet. Each tablet contains Sodium Alginate BP 500 mg & Potassium Bicarbonate BP 100 mg.

SK+F

Manufactured by

ESKAYEF BANGLADESH LIMITED

GAZIPUR, BANGLADESH

® REGD. TRADEMARK

PM03396 V01